SEC Company Response from ACADIA PHARMACEUTICALS INC (ACAD) (CIK 0001070494) (ACAD) — Sep 22, 2008
ACADIA PHARMACEUTICALS INC (ACAD) (CIK 0001070494)
Date: Sept. 22, 2008 · CIK: 0001070494 · Accession: 0001193125-08-199408
AI Filing Summary & Sentiment
File numbers found in text: 333-153347
Letter
Acceleration Request
September 22, 2008
VIA FACSIMILE AND EDGAR
United States Securities and Exchange Commission
Mail Stop 6010
100 F Street N.E.
Washington, D.C. 20549
Attn: Jeffrey P. Riedler
Sebastian Gomez Abero
RE: ACADIA Pharmaceuticals Inc.
Registration Statement on Form S-3 (File No. 333-153347)
Ladies and Gentlemen:
The undersigned registrant hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective on September 23, 2008, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable.
In connection with this request, the Company acknowledges that:
•
should the Commission or the staff of the Commission (the “Staff”), acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
•
the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
•
the Company may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Until such time as it becomes effective, the above-referenced Registration Statement will continue to be subject to the delaying amendment set forth therein.
Very truly yours,
ACADIA PHARMACEUTICALS INC.
Show Raw Text
CORRESP 1 filename1.htm Acceleration Request September 22, 2008 VIA FACSIMILE AND EDGAR United States Securities and Exchange Commission Mail Stop 6010 100 F Street N.E. Washington, D.C. 20549 Attn: Jeffrey P. Riedler Sebastian Gomez Abero RE: ACADIA Pharmaceuticals Inc. Registration Statement on Form S-3 (File No. 333-153347) Ladies and Gentlemen: The undersigned registrant hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective on September 23, 2008, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable. In connection with this request, the Company acknowledges that: • should the Commission or the staff of the Commission (the “Staff”), acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; • the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and • the Company may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Until such time as it becomes effective, the above-referenced Registration Statement will continue to be subject to the delaying amendment set forth therein. Very truly yours, ACADIA PHARMACEUTICALS INC. /s/ Glenn F. Baity Glenn F. Baity Vice President and General Counsel